Experience

Femasys Inc.

• United States
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Chief Financial Officer

  • Feb 2022 - 1 year 11 months

  Suwanee, Georgia, United States Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only… Show more Femasys is a biomedical company focused on transforming women’s healthcare worldwide by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. With an initial focus in the area of reproductive health, its two lead product candidates offer solutions to improve patient care and health economics: FemBloc®, a first and only non-surgical product for permanent birth control and FemaSeed™, a first and only directed sperm delivery product for infertility treatment. Femasys’ FemVue® product for fallopian tube assessment by ultrasound is currently marketed in the United States as its main commercial priority. Femasys has also developed a novel technology platform for tissue sampling intended to be marketed alongside our other women-specific medical products in the physician’s office setting. Show less



Cellectar Biosciences, Inc.

• Biotechnology
• 1 - 100 Employee

• Vice President and Chief Financial Officer

  • Sep 2019 - Feb 2022

  Florham Park, NJ Cellectar is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugates™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next… Show more Cellectar is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugates™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations. Show less



Akari Therapeutics Plc

• Chief Financial Officer

  • Jan 2012 - Sep 2019

  New York, NY Akari a clinical-stage biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system and the bioamine system for the treatment of rare and orphan diseases.



Althera Medical

• Chief Financial Officer

  • Apr 2011 - Jan 2012



DE Consulting Group

• President

  • Apr 2009 - Jan 2012

  A financial and business strategy consulting firm. • Corporate Leadership and Governance - advised CEO, Board of Directors and Audit Committees on financial control processes and critical business metrics. Mentored senior and middle financial managers. • Cash Flow Modeling and Projection Tool - created new management reporting system and acted as a catalyst for change implementing company-wide performance improvements, including relationships with lenders. • Accounting and… Show more A financial and business strategy consulting firm. • Corporate Leadership and Governance - advised CEO, Board of Directors and Audit Committees on financial control processes and critical business metrics. Mentored senior and middle financial managers. • Cash Flow Modeling and Projection Tool - created new management reporting system and acted as a catalyst for change implementing company-wide performance improvements, including relationships with lenders. • Accounting and Financial Reporting - assisted in reengineering of accounting discipline, financial reporting and SEC filings at SEC registrants; established formal closing procedures and timelines. • Business Advisory Solutions - implemented internal controls including assisting public entities with Sarbanes-Oxley compliance. Participated in filing of application for tax benefit program with the New Jersey Economic Development Authority. Show less



Lev Pharmaceuticals, Inc.

• Corporate Controller

  • Mar 2007 - Feb 2009

  Greater New York City Area



EpiCept Corporation

• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Controller & VP, Finance & Administration

  • Dec 1999 - Mar 2007